Literature DB >> 8106963

Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus.

T Wrin1, L Crawford, L Sawyer, P Weber, H W Sheppard, C V Hanson.   

Abstract

Although laboratory-adapted strains of human immunodeficiency virus (HIV) are generally highly sensitive to neutralization by HIV-positive patient sera, we have found a more complex pattern of cross-neutralization and neutralization resistance among low-passage clinical isolates. These HIV isolates, like many other lentiviruses, resisted neutralization by the patient's own (autologous) antibodies. We assessed the degree of antigenic relatedness between different patient isolates of HIV through cross-neutralization with heterologous sera and virus isolates. Complicated patterns emerged, with variation in breadth of neutralization among individual plasmas and variation in frequency of neutralization among isolates. In longitudinal studies of individuals, we found that some but not all such patients develop a neutralizing response that "catches up" with their earlier isolates after a lag period. Taken together, these data suggest that an individual's immune response broadens with time because of cumulative exposure to multiple antigenic variants that arise throughout HIV disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8106963

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  33 in total

1.  Neutralization profiles of sera from human immunodeficiency virus (HIV)-infected individuals: relationship to HIV viral load and CD4 cell count.

Authors:  M Nokta; P Turk; K Loesch; R B Pollard
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

Review 2.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

3.  Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.

Authors:  T D Lockey; K S Slobod; T E Caver; S D'Costa; R J Owens; H M McClure; R W Compans; J L Hurwitz
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

4.  A Multi-Vector, Multi-Envelope HIV-1 Vaccine.

Authors:  Julia L Hurwitz; Xiaoyan Zhan; Scott A Brown; Mattia Bonsignori; John Stambas; Timothy D Lockey; Bart Jones; Sherri Surman; Robert Sealy; Pam Freiden; Kristen Branum; Karen S Slobod
Journal:  J Pediatr Pharmacol Ther       Date:  2007-04

5.  The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain.

Authors:  M Schreiber; C Wachsmuth; H Müller; S Odemuyiwa; H Schmitz; S Meyer; B Meyer; J Schneider-Mergener
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

6.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

7.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

8.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine.

Authors:  P Mazzetti; S Giannecchini; D Del Mauro; D Matteucci; P Portincasa; A Merico; C Chezzi; M Bendinelli
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

9.  Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.

Authors:  Xueling Wu; Tongqing Zhou; Sijy O'Dell; Richard T Wyatt; Peter D Kwong; John R Mascola
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

10.  SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development?

Authors:  Robert Sealy; Xiaoyan Zhan; Timothy D Lockey; Louis Martin; James Blanchard; Vicki Traina-Dorge; Julia L Hurwitz
Journal:  Curr HIV Res       Date:  2009-09       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.